Article PDF
References
Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S, Hepatitis C Intervention Therapy Group: Pegylated interferon-α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 68:556–567, 2000
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling MH, Albrecht JK, International Hepatitis Interventional Therapy Group: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358:958–965, 2001
Sonnenblick M, Rosin AJ: Cardiotoxicity of interferon: A review of 44 cases. Chest 99:557–561, 1991
Conlon KC, Urba WJ, Smith JW2nd, Steis RG, Longo DL, Clark JW: Exacerbation of symptoms of autoimmune disease in patients receiving alphainterferon therapy. Cancer 65:2237–2242, 1990
Chin K, Tabata C, Sataka N, Nagai S, Moriyasu F, Kuno K: Pneumonitis associated with natural and recombinant Interferon Alfa therapy for chronic hepatitis C. Chest 105:939–941, 1994
Ishizaki T, Sasaki F, Ameshima S, Shiozaki K, Takahashi H, Abe Y, Ito S, Kuriyama M, Nakai T, Kitagawa M: Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis. Eur Respir J 9:2691–2696, 1996
Abi-Nassif S, Mark EJ, Fogel RB, Hallisey RK: Pegylated interferon and ribavirin induced interstitial pneumonitis with ARDS. Chest 124:406–410, 2003.
Ogata K, Koga T, Yagawa K: Interferon-related bronchiolitis obliterans organizing pneumonia. Chest 106:612–613, 1994
Tahan V, Ozseker F, Guneylioglu D, Baran A, Ozaras R, Mert A, Ucisik AC, Cagatay T, Yilmazabayhan D, Senturk H: Sarcoidosis after use of interferon for chronic hepatitis C. Dig Dis Sci 48:169–173, 2003
Bini EJ, Weinshel EH: Severe exacerbation of Asthma: A new side effect of interferon-α in patients with Asthma and chronic hepatitis C. Mayo Clin Proc 74:367–370, 1994
Bedossa P, Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The META VIR Cooperative Study Group. Hepatology 24:289–293, 1996
Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, Rassam S, Fryden A, Reesink H, Bassendine M, Norkrans G, Cuypers T, Lelie N, Telfer P, Watson J, Weegink C, Sillikens P, Weiland O: Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo controlled study. J Hepatol 25:591–598, 1996
Abbas AK, Lichtman AH, Pober JS (eds): Effector mechanism of immune responses. In: Cellular and Molecular Immunology. Philadelphia, Saunders, pp 235–335, 2000
Ueda T, Ohta K, Suzuki N, Yamaguchi M, Hirai K, Horiuchi T, Watanabe J, Miyamoto T, Ito K: Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. Am Rev Respir Dis 146:266–268, 1992
Irving WL, Day S, Johnston ID: Idiopathic pulmonary fibrosis and hepatitis C virus infection. Am Rev Respir Dis 148:1683–1684, 1993
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fuhrmann, V., Kramer, L., Bauer, E. et al. Case Report: Severe Interstitial Pneumonitis Secondary to Pegylated Interferon α-2b and Ribavirin Treatment of Hepatitis C Infection. Dig Dis Sci 49, 1966–1970 (2004). https://doi.org/10.1007/s10620-004-9602-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-004-9602-3